Supercharged vaccine could offer strong protection with just one dose
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.
One combination of methods led to a 44 percent increase in child immunizations.
MIT engineers designed polymer microparticles that can deliver vaccines at predetermined times after injection.
Their study yielded hundreds of “cryptic” peptides that are found only on pancreatic tumor cells and could be targeted by vaccines or engineered T cells.
When his son received a devastating diagnosis, Fernando Goldsztein MBA ’03 founded an initiative to help him and others.
The nanoparticle-based vaccine shows promise against many variants of SARS-CoV-2, as well as related sarbecoviruses that could jump to humans.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
MIT engineers’ new model could help researchers glean insights from genomic data and other huge datasets.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.
MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.
While women and men self-reported similar vaccination rates, unvaccinated women had less intention to get vaccinated than men.
Study shows metal-organic particles can both deliver vaccines and act as an adjuvant to generate a strong immune response at a lower dose.
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
Award honors “scientists who have made a transformational contribution toward the improvement of human health.”
Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.